```html

Adenocarcinoma of the Lung – A Patient‑Friendly Medical Guide

Overview

Adenocarcinoma of the lung is a type of non‑small cell lung cancer (NSCLC) that begins in the glandular (secretory) cells that line the airways. It is the most common histologic subtype of lung cancer, accounting for about 40–45% of all lung cancers in the United States.<sup>1</sup>

Who it affects: Historically considered a disease of smokers, adenocarcinoma now also occurs in never‑smokers, especially women and people of East Asian ancestry. The median age at diagnosis is 70 years, but cases are reported in patients as young as their 30s.

Prevalence: Lung cancer is the leading cause of cancer death worldwide, responsible for ~1.8 million deaths annually (WHO 2023).<sup>2</sup> Among NSCLC subtypes, adenocarcinoma is the most frequently diagnosed, partly because it tends to arise in the outer peripheral parts of the lung where routine chest imaging more readily detects it.

Symptoms

Early adenocarcinoma often causes no symptoms. When the tumor grows, it may produce the following signs. The presence of any symptom should prompt a conversation with a health‑care professional.

Respiratory symptoms

• Persistent cough – may be dry or produce sputum.
• Shortness of breath (dyspnea) – especially with exertion.
• Wheezing or noisy breathing – occurs if the tumor partially blocks an airway.
• Chest pain – often a dull, persistent ache that may worsen with deep breathing or coughing.
• Hemoptysis – coughing up blood or blood‑tinged sputum; this is a red‑flag symptom.

Systemic symptoms

• Unexplained weight loss – losing >10 % of body weight without trying.
• Fatigue – persistent tiredness not relieved by rest.
• Loss of appetite.
• Fever or night sweats – occasional low‑grade fevers without infection.

Symptoms from metastasis (spread)

• Bone pain – especially in the back, hips, or ribs.
• Neurologic deficits – headaches, seizures, or weakness if cancer spreads to the brain.
• Swelling in the neck or face – may indicate involvement of major veins (superior vena cava syndrome).
• Persistent abdominal discomfort – could suggest spread to the liver or adrenal glands.

Causes and Risk Factors

Unlike many single‑cause diseases, adenocarcinoma results from a combination of genetic mutations and environmental exposure.

Major risk factors

• Smoking – even low‑intensity or past smoking raises risk; carcinogens damage DNA in airway cells.
• Secondhand smoke – exposure in the home or workplace.
• Radon gas – the leading cause of lung cancer among non‑smokers; indoor radon levels >4 pCi/L increase risk (CDC 2022).<sup>3</sup>
• Occupational exposures – asbestos, silica, diesel exhaust, and certain metal fumes.
• Family history/genetic predisposition – mutations in EGFR, KRAS, ALK, ROS1, or HER2 can be inherited or arise spontaneously.
• Chronic lung diseases – COPD, pulmonary fibrosis, and prior lung infections may increase susceptibility.
• Age & gender – risk rises after age 55; women, particularly of Asian descent, have a higher proportion of EGFR‑mutated adenocarcinomas.

Underlying biological mechanisms

The disease begins when DNA damage leads to oncogenic mutations—most commonly in the KRAS, EGFR, ALK, and TP53 genes. These mutations drive uncontrolled cell growth, resistance to apoptosis (programmed cell death), and the ability to invade surrounding tissues.

Diagnosis

Diagnosing lung adenocarcinoma involves a stepwise approach that combines imaging, tissue sampling, and molecular testing.

Initial evaluation

• Medical history & physical exam – focuses on symptom duration, smoking history, and occupational exposures.
• Chest X‑ray – low‑cost first line; may reveal a peripheral nodule or mass.

Advanced imaging

• Computed Tomography (CT) scan – thin‑slice CT provides detailed anatomy, assesses tumor size, and detects mediastinal lymph node involvement.
• Positron Emission Tomography (PET‑CT) – evaluates metabolic activity and helps stage disease by identifying distant metastases.
• Magnetic Resonance Imaging (MRI) – especially of the brain when neurologic symptoms are present.

Histologic confirmation

Imaging alone cannot differentiate cancer types; tissue is required.

• Bronchoscopy with biopsy – used for centrally located lesions.
• CT‑guided percutaneous needle biopsy – preferred for peripheral nodules typical of adenocarcinoma.
• Video‑assisted thoracoscopic surgery (VATS) – minimally invasive surgical biopsy when percutaneous methods are inconclusive.

Molecular and biomarker testing

Guides targeted therapy. Recommended tests include:

• EGFR mutation analysis
• ALK and ROS1 rearrangement testing
• KRAS mutation, BRAF V600E, MET exon 14 skipping, NTRK fusions
• PD‑L1 expression (immunotherapy eligibility)

Staging

The TNM system (Tumor size, Node involvement, Metastasis) is used. Stages I–IV correspond to increasing disease spread and determine treatment strategy (American Cancer Society 2023).<sup>4</sup>

Treatment Options

Treatment is individualized based on stage, molecular profile, patient performance status, and comorbidities. Below is a summary of the main modalities.

Surgery

• Indications – early‑stage (I–II) disease with no mediastinal nodal spread.
• Procedures – lobectomy (removal of a lung lobe) is standard; segmentectomy or wedge resection may be considered for small peripheral tumors (<5 cm).
• Minimally invasive approaches – VATS or robotic‑assisted surgery reduce postoperative pain and length of stay.

Radiation therapy

• Stereotactic body radiotherapy (SBRT) – high‑dose, precise radiation for medically inoperable early‑stage tumors.
• Conventional fractionated radiotherapy – used in locally advanced (stage III) disease, often combined with chemotherapy.

Chemotherapy

Platinum‑based doublet regimens (e.g., cisplatin + pemetrexed) are standard for stage II‑IV disease without actionable mutations.

Targeted therapy

Effective for tumors with specific driver mutations:

• EGFR mutations – osimertinib, erlotinib, gefitinib.
• ALK rearrangements – alectinib, brigatinib, lorlatinib.
• ROS1, MET, BRAF, NTRK – respective inhibitors (e.g., crizotinib for ROS1, capmatinib for MET).

These agents are taken orally and often have fewer systemic side effects than chemotherapy.

Immunotherapy

For tumors with high PD‑L1 expression (≥1 %) or after chemotherapy failure:

• Pembrolizumab, atezolizumab, or nivolumab (PD‑1/PD‑L1 inhibitors).
• Combination regimens (e.g., pembrolizumab + chemotherapy) improve survival in stage III‑IV disease.

Supportive & palliative care

• Oxygen therapy for chronic dyspnea.
• Pain management using NSAIDs, opioids, or nerve blocks.
• Management of cough, breathlessness, and psychosocial support.

Lifestyle modifications that complement treatment

• Smoking cessation – reduces recurrence risk and improves treatment tolerance.
• Regular physical activity (as tolerated) – helps maintain functional capacity.
• Balanced nutrition – adequate protein intake supports healing.

Living with Adenocarcinoma of the Lung

Adapting daily life can improve quality of life and treatment outcomes.

Practical tips

• Medication adherence – use pill organizers or phone reminders; discuss side‑effects promptly with your oncologist.
• Follow‑up schedule – most patients have CT scans every 3–6 months for the first 2 years, then annually.
• Energy conservation – break activities into short intervals, rest before feeling fatigued.
• Respiratory exercises – pursed‑lip breathing and diaphragmatic breathing can reduce dyspnea.
• Vaccinations – annual influenza vaccine and COVID‑19 boosters lower infection risk; pneumococcal vaccine is recommended.
• Support networks – join lung‑cancer support groups, either in‑person or online (e.g., American Lung Association).
• Psychological health – counseling, mindfulness, or cognitive‑behavior therapy can mitigate anxiety and depression.

Nutrition

Goal: maintain weight and muscle mass.

• Eat 5–6 small meals rich in lean protein (fish, poultry, beans).
• Include omega‑3 fatty acids (salmon, walnuts) for anti‑inflammatory benefits.
• Limit processed foods, sugary drinks, and excessive salt.

Physical activity

Even light activity (walking 10–15 minutes, gentle yoga) improves stamina and mood. Consult a physiotherapist for a tailored program, especially after surgery or during chemotherapy.

Prevention

While not all cases are preventable, risk can be markedly reduced.

• Never start smoking; if you smoke, quit—use nicotine replacement therapy, varenicline, or counseling.
• Test homes for radon and mitigate if levels exceed 4 pCi/L (EPA 2022).<sup>5</sup>
• Occupational safety – wear protective equipment in jobs with asbestos, silica, or diesel exhaust exposure.
• Healthy diet & regular exercise – diets rich in fruits, vegetables, and whole grains are associated with lower lung‑cancer risk.
• Vaccination against respiratory infections – reduces chronic inflammation that could predispose to malignancy.

Complications

If left untreated or if disease progresses, several serious complications may arise.

• Respiratory failure – due to tumor obstruction or extensive parenchymal disease.
• Pneumothorax – air leakage into the pleural space, especially after percutaneous biopsy.
• Superior vena cava (SVC) syndrome – facial swelling, distended neck veins, and headache from venous obstruction.
• Bone metastases – pathologic fractures, spinal cord compression.
• Brain metastases – seizures, focal neurologic deficits, increased intracranial pressure.
• Paraneoplastic syndromes – e.g., hypercalcemia, hyponatremia, or clotting disorders.
• Treatment‑related toxicities – chemotherapy‑induced neutropenia, radiation‑induced pneumonitis, immunotherapy‑related colitis or pneumonitis.

When to Seek Emergency Care

---

Sources:

1. Mayo Clinic. “Lung cancer - types, symptoms, and treatment.” 2023. link.
2. World Health Organization. “Cancer Fact Sheets.” 2023. link.
3. Centers for Disease Control and Prevention. “Radon and Lung Cancer.” 2022. link.
4. American Cancer Society. “Lung Cancer Staging.” 2023. link.
5. U.S. Environmental Protection Agency. “Radon Mitigation.” 2022. link.
6. National Cancer Institute. “Non‑Small Cell Lung Cancer Treatment (PDQ®) – Health Professional Version.” 2024. link.

```